A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Genotype 1 HCV Infection

Trial Profile

A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Genotype 1 HCV Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2016

At a glance

  • Drugs Sofosbuvir/velpatasvir (Primary) ; Voxilaprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 17 Apr 2016 Pooled analysis of 2 studies - GS-US-367-1168 and GS-US-367-1169 (n=130) were presented at The International Liver Congress™ 2016.
    • 16 Apr 2016 Results published in a Gilead Sciences media release.
    • 16 Apr 2016 Combined results from this and another phase II trial (CTP 700254491) presented at the The International Liver Congress 2016, according to a Gilead Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top